Mylan keeps EpiPen costs high despite intense public scrutiny

Mylan faced a firestorm of criticism last year for the high price of EpiPens, which increased nearly 400 percent since 2004. Despite immense public scrutiny, a CMS rebate scandal and several federal hearings all spurred by the product's price, a two-pack of EpiPens maintains its $609 list price, according to The New York Times.

The publication spoke with 10 former Mylan executives who said they were not surprised the price is still so high. The unnamed executives said the drugmaker "has thrived by learning to absorb, and then ignore, opprobrium," according to The New York Times.

"The company has an effective monopoly on a lifesaving product, which has allowed its leaders to see public outrage as a tax they must pay, and then move on," they added.

Mylan CEO Heather Bresch spoke to The New York Times last month, citing a flawed healthcare system as the reason for high drug costs. She called Mylan "a pretty rare and unconventional company" focused on offering inexpensive drugs, according to the report.

"Look at what we've built and what we deliver day-in and day-out," she told The New York Times. "[A]t the center of all of that is the patient."

More articles on supply chain:

Patterson Companies fires CEO in wake of second straight annual profit drop
7 must-reads for supply chain leaders this week
C-suites containing supply chain leaders have better operational performance: 7 survey insights

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars